Navigation Links
SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome
Date:12/9/2011

SAN ANTONIOResearchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with better clinical outcomes. This is a new marker to identify the subset of these patients who may respond positively to chemotherapy.

Today, no such marker is applied in care of triple negative breast cancer, and as a result, patients are all treated the same.

Agnieszka Witkiewicz, M.D., Associate Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, and Erik Knudsen, Ph.D., Professor of Cancer Biology and Deputy Director of Basic Science at Jefferson's Kimmel Cancer Center, discussed the findings at the 2011 CTRC‑AACR San Antonio Breast Cancer Symposium during a poster discussion.

"This is a step in trying to better direct treatment for patients with triple negative breast cancer," Dr. Knudsen said.

In general for cancer, loss of tumor suppressor genes is associated with poor clinical outcome. However, loss of RB in triple negative breast cancer patients appears to be a predictor of favorable clinical outcomes. This is because it changes the way tumor cells respond to therapy such that they end up becoming more sensitive to chemotherapy.

The researchers retrospectively evaluated the RB status and clinical outcome of a cohort of 220 patients diagnosed and treated at Thomas Jefferson University Hospital with chemotherapy. RB loss, they found, was associated with a longer overall survival. In contrast, patients with RB had worse survival.

"Triple negative breast cancer is the most deadly of breast cancers, with fast-growing tumors, that affects younger women," said Dr. Witkiewicz. "This work allowed us to identify a marker that could lead to better treatment for patients. It's about female personalized medicine."

Edith Mitchell, M.D., Professor of Medical Oncology at Jefferson, and Adam Ertel, Ph.D., a research instructor in the Department of Cancer Biology, were also involved in the study.

The next step for the researchers is a clinical trial at Jefferson to confirm their findings. Tumors of newly-diagnosed patients with triple negative breast cancer will be tested for the RB gene before they receive chemotherapy. After treatment, the data will be evaluated to determine the efficacy of directing future patient care.


'/>"/>
Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. First genome sequencing clinical trial for triple negative cancer points to new treatments
2. First whole-genome sequencing clinical trials for triple-negative breast cancer presented
3. Deaths From Abuse of Painkillers Triple in a Decade: CDC
4. Cases of Legionnaires Disease Tripled in 10 Years
5. Triple therapy regime puts patients with leukemic form of cutaneous lymphoma in remission
6. Different subtypes of triple-negative breast cancer respond to different therapies
7. Treatment for Abuse of Anti-Anxiety Drugs Tripled Over 10 Years
8. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
9. Nationwide utilization of virtual colonoscopy triples, study suggests
10. Philanthropic pledge triples funds for TGen ovarian cancer research
11. Multiple childbirth linked to increased risk of rare, aggressive triple-negative breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey firm ... is launching a charity drive to raise awareness of heart disease and promote habits ... America, and is responsible for 1 in every 4 deaths at the national level ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education ... Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on ... announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra Lee ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve ... State University’s Athletic Training Education program forged a relationship built upon the foundation ... Program, which is consists of both student members and certified members of the ...
(Date:1/16/2017)... Village, IL (PRWEB) , ... January 16, 2017 ... ... personal audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at ... Convention Center in Las Vegas, Booth #2809. The SHOT Show is the shooting, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Permobil has just ... brand of custom seating systems has a well-earned reputation for premium quality, with ... for innovation and growth in the custom seating business, which enjoys strong demand, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market 2016-2020" report to their offering. ... The global laparotomy sponges market to ... Global Laparotomy Sponges Market 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:1/17/2017)...  ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ... Quinn Ph.D as Vice President Corticotropin Regulatory Affairs, ... Karen Quinn is a professional with over ... Affairs, specifically with a focus on drug products ... most recently with Takeda Pharmaceuticals International as Senior ...
(Date:1/17/2017)... , Jan. 17, 2017  Bayer today announced the appointment ... Pharmaceuticals business in the Americas, comprising the United ... Latin America . In this role, Dr. ... the Board of Management of Bayer AG and President of ... highly respected leader in the pharmaceutical industry and I,m delighted ...
Breaking Medicine Technology: